J&J pitches its top 11 drugs in the pipeline — with a peak sales promise of $1B-plus
Joaquin Duato at an Endpoints News event in San Francisco on January 10, 2017
Over the last six years, J&J has nailed 11 new drug approvals. Looking forward over the next five years, the pharma giant is forecasting that it can double that, with more than 10 new approvals for blockbuster meds out of its late-stage pipeline. And it needs them all to keep up with an ambitious growth forecast for its pharma division revenue.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters